These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032 [TBL] [Abstract][Full Text] [Related]
10. Utility of novel androgen receptor therapies in the real world: A nuanced approach. Dhawan M; Ryan CJ Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893 [TBL] [Abstract][Full Text] [Related]
11. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320 [TBL] [Abstract][Full Text] [Related]
12. The evolving role of enzalutamide on the treatment of prostate cancer. Nadal R; Bellmunt J Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021 [TBL] [Abstract][Full Text] [Related]
13. Increased survival with enzalutamide in prostate cancer after chemotherapy. Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS; N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553 [TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. Graff JN; Gordon MJ; Beer TM Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355 [TBL] [Abstract][Full Text] [Related]
15. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide in metastatic prostate cancer before chemotherapy. Froehner M; Wirth MP N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112 [No Abstract] [Full Text] [Related]
17. Enzalutamide in metastatic prostate cancer before chemotherapy. Beer TM; Tombal B N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111 [No Abstract] [Full Text] [Related]
18. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer. Keating GM Drugs Aging; 2015 Mar; 32(3):243-9. PubMed ID: 25711765 [TBL] [Abstract][Full Text] [Related]
19. Practical guide to the use of enzalutamide. Hoffman-Censits J; Kelly WK Can J Urol; 2014 Apr; 21(2 Supp 1):64-9. PubMed ID: 24775726 [TBL] [Abstract][Full Text] [Related]
20. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy. Althaus A; Kibel A Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395 [No Abstract] [Full Text] [Related] [Next] [New Search]